At the upcoming Keystone Symposia meeting on “Tumor Metabolism,” journal editors will share their insights into the publishing process, and how to maximize the impact factor of your research at a special “Meet the Editors” Workshop. Panelists will include a diverse array of editors from various high impact journals, including:
- EMBO: Deniz Senyilmaz Tiebe
- Journal of Cell Biology: Tim Spencer
- Cancer Discovery: Michele M. Hartsough
- Cell Press: Sejal K. Vyas, Allyson Evans & Krista Lynn Bledsoe
- Nature Publications:
- Barbara Marte (Nature)
- Elena Bellafante (Nature Metabolism)
- Alexia-Ileana Zaromytidou (Nature Cancer)
- Ulrike Harjes (Nature Reviews Cancer)
- Maria Garcia-Fernandez (Nature Communications)
The workshop, and the meeting, will be an important opportunity for scientists to connect with editors face-to-face, and establish contacts and relationships that will serve them throughout their research careers. These mutually beneficial relationships provide an essential foundation for both parties to pursue and publish the highest quality research possible, by opening lines of communication.
Here we catchup with EMBO Reports Editor Dr. Deniz Senyilmaz Tiebe, who will be a leading voice in the “Meet the Editors” Workshop at the Tumor Metabolism meeting
She shares her thoughts about the trajectory of the field, and the meeting program, which brings together leaders in tumor metabolism research to address key questions regarding:
- the unique metabolic features of tumors versus healthy proliferating cells
- associated opportunities for therapeutic intervention
- applications at the interface between metabolism and immunotherapy
Follow up-to-the-minute coverage of the “Tumor Metabolism” meeting on Twitter:
In this Q/A, Deniz provides some insights into the publishing process and the field of Tumor Metabolism
Why are you attending this conference? What do you hope to get out of it?
Dr. Senyilmaz Tiebe: As an editor, I regularly attend conferences to stay on top of the topics that I cover at EMBO Reports in terms of progress in the field, but also standards/state of art experimentation methods.
- Furthermore, we make contacts for referees and ideally also future authors of research papers, which is why the presentation of unpublished data is essential for us as editors.
- Last but not least, we try to share our policies and standards at EMBO Press for fair, transparent publication with a broader audience.
Keystone Symposia meetings offer a unique breadth and depth of perspectives on a given subject, and a superb speaker list which is geographically and gender balanced– these meetings are therefore are very attractive for me as an editor.
How does this conference fit into the research landscape of the field?
Dr. Senyilmaz Tiebe:Tumor Metabolism is not a new field, yet it is a field that moves quite fast. Therefore it is important to hold and attend regular meetings so as not to lose touch with new findings and be able to place them in a context. This Keystone Symposia meeting brings together field leaders from multiple sub-disciplines of Tumor Metabolism ranging from immunometabolism, to signaling and translational applications.
In particular, I am confident that the cancer-immune interplay session featuring talks that focus on ‘immunometabolism’ will be quite exciting. Immunometabolism is newly emerging from two fields that have been considered to be separate from each other until recently.
Accumulating evidence supports that immunity and metabolism are more closely interlinked than anticipated. Metabolic status of immune cells has a strong impact on their function, which is clinically relevant and constitutes a potential therapeutic target for cancer, metabolic diseases and autoimmunity.
I believe this topic will spark many fruitful discussions.
What sessions, speakers and/or special workshops are you most looking forward to and why?
Dr. Senyilmaz Tiebe:This meeting offers multiple sessions that are very exciting. If I had to choose, one would be the ‘molecular determinants of cell fate’ session. I find the concept of metabolites acting as signaling molecules rather than just being by-products of metabolic pathways quite fascinating. I am confident that there will be exciting stories and lively discussions during this session. Moreover, I am looking forward to the ‘cancer-immune interplay’ session and hearing about how immune cells affect tumor growth.
How does this meeting fit into your publication’s recent coverage of this field?
Dr. Senyilmaz Tiebe:We are very interested in the topic and publish quite a lot of research papers.
We have put together an exciting collection of articles recently published on tumor metabolism across all of the EMBO Press journals, which highlights the interplay between metabolic pathways and cancer progression, and how exploiting this interplay can be used as targeted therapy.
This collection is freely available at https://www.embopress.org/page/journal/14693178/focus
About the Author:
Deniz Senyilmaz Tiebe, PhD
Deniz received her PhD in 2015 from the University of Heidelberg, Germany. During her PhD work in the laboratory of Aurelio Teleman at the German Cancer Research Center, she uncovered a dedicated signaling pathway through which stearic acid regulates mitochondrial morphology and function. During her post-doc, one of her projects focused on the effects of dietary stearic acid on human physiology.
Deniz joined EMBO reports in November 2018.
tel: +49 6221 8891 014